Eckert & Ziegler Strahlen- und Medizintechnik AG (0NZY.L)
| Previous close | 142.53 |
| Open | 145.42 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 137.04 - 147.20 |
| 52-week range | 137.04 - 147.20 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 727.447M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 109.10 |
| EPS (TTM) | 1.30 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Eckert & Ziegler with Sales Growth in the First Quarter of 2022
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter ResultsEckert & Ziegler with Sales Growth in the First Quarter of 2022 12.05.2022 / 07:45 The issuer is solely responsible for the content of this announcement.Berlin, 12 May 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 million in the first quarter of 2022. The net profit of EUR 6.7 million or EUR 0.32 per share was below the previous yea
- EQS Group
Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): AllianceEckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes 11.05.2022 / 09:16 The issuer is solely responsible for the content of this announcement.Berlin, 11 May 2022. Eckert & Ziegler AG (ISIN DE0005659700, TecDAX), a specialist in medical radioisotopes, has entered into a long-term cooperation agreement with the Nuclear Physics Institute of the Czech Academy of Scie
- EQS Group
Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance/Study08.04.2022 / 10:14 The issuer is solely responsible for the content of this announcement.Berlin / Nijmegen, 8 April 2022. Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.Developed by PentixaPharm, PE
